HES6 enhances the motility of alveolar rhabdomyosarcoma cells

Experimental Cell Research

Volumn 319, Issue 1, 2013, Pages 103-112

  Wickramasinghe, Caroline M ^a   Domaschenz, Renae ^a,d   Amagase, Yoko ^a,c   Williamson, Daniel ^b,e   Missiaglia, Edoardo ^b   Shipley, Janet ^b   Murai, Kasumi ^a   Jones, Philip H ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Actin; Cancer; Motility; Proliferation; Transgelin

Indexed keywords

HAIRY ENHANCEROF SPLIT 6 PROTEIN; MESSENGER RNA; PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; TRANSGELIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; FUSION GENE; GENE SILENCING; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHABDOMYOSARCOMA; SARCOMA CELL;

EID: 84869092256     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.08.010     Document Type: Article

References (51)

1. Meza J.L., Anderson J., Pappo A.S., Meyer W.H. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J. Clin. Oncol. 2006, 24:3844-3851.
2. Clark J., Rocques P.J., Braun T., Bober E., Arnold H.H., Fisher C., Fletcher C., Brown K., Gusterson B.A., Carter R.L., et al. Expression of members of the myf gene family in human rhabdomyosarcomas. Br. J. Cancer. 1991, 64:1039-1042.
3. Dias P., Parham D.M., Shapiro D.N., Webber B.L., Houghton P.J. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am. J. Pathol. 1990, 137:1283-1291.
4. Tapscott S.J., Thayer M.J., Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 1993, 259:1450-1453.
5. Merlino G., Helman L.J. Rhabdomyosarcoma-working out the pathways. Oncogene 1999, 18:5340-5348.
6. Davis R.J., D'Cruz C.M., Lovell M.A., Biegel J.A., Barr F.G. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994, 54:2869-2872.
7. Barr F.G., Galili N., Holick J., Biegel J.A., Rovera G., Emanuel B.S. Rearrangement of the PAX3 paired box gene in the paediatric solid tumor alveolar rhabdomyosarcoma. Nat. Genet. 1993, 3:113-117.
8. Sorensen P.H., Lynch J.C., Qualman S.J., Tirabosco R., Lim J.F., Maurer H.M., Bridge J.A., Crist W.M., Triche T.J., Barr F.G. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 2002, 20:2672-2679.
9. Williamson D., Missiaglia E., de Reynies A., Pierron G., Thuille B., Palenzuela G., Thway K., Orbach D., Lae M., Freneaux P., Pritchard-Jones K., Oberlin O., Shipley J., Delattre O. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 2010, 28:2151-2158.
10. Davicioni E., Anderson M.J., Finckenstein F.G., Lynch J.C., Qualman S.J., Shimada H., Schofield D.E., Buckley J.D., Meyer W.H., Sorensen P.H., Triche T.J. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am. J. Pathol. 2009, 174:550-564.
11. Anderson J., Gordon T., McManus A., Mapp T., Gould S., Kelsey A., McDowell H., Pinkerton R., Shipley J., Pritchard-Jones K. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?. Br. J. Cancer 2001, 85:831-835.
12. Cao L., Yu Y., Bilke S., Walker R.L., Mayeenuddin L.H., Azorsa D.O., Yang F., Pineda M., Helman L.J., Meltzer P.S. Genome-wide identification of PAX3-FKHR binding sites in Rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010, 70:6497-6508.
13. Fischer A., Gessler M. Delta-Notch-and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res. 2007, 35:4583-4596.
14. Kageyama R., Ohtsuka T., Kobayashi T. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development 2007, 134:1243-1251.
15. Gao X., Chandra T., Gratton M.O., Quelo I., Prud'homme J., Stifani S., St-Arnaud R. HES6 acts as a transcriptional repressor in myoblasts and can induce the myogenic differentiation program. J. Cell Biol. 2001, 154:1161-1171.
16. Kawamura A., Koshida S., Hijikata H., Sakaguchi T., Kondoh H., Takada S. Zebrafish hairy/enhancer of split protein links FGF signaling to cyclic gene expression in the periodic segmentation of somites. Genes Dev. 2005, 19:1156-1161.
17. Pissarra L., Henrique D., Duarte A. Expression of hes6, a new member of the Hairy/Enhancer-of-split family, in mouse development. Mech. Dev. 2000, 95:275-278.
18. Cossins J., Vernon A.E., Zhang Y., Philpott A., Jones P.H. Hes6 regulates myogenic differentiation. Development 2002, 129:2195-2207.
19. Vasiliauskas D., Stern C.D. Expression of mouse HES-6, a new member of the Hairy/Enhancer of split family of bHLH transcription factors. Mech. Dev. 2000, 98:133-137.
20. Malone C.M., Domaschenz R., Amagase Y., Dunham I., Murai K., Jones P.H. Hes6 is required for actin cytoskeletal organization in differentiating C2C12 myoblasts. Exp. Cell Res. 2011, 317:1590-1602.
21. Murai K., Vernon A.E., Philpott A., Jones P. Hes6 is required for MyoD induction during gastrulation. Dev. Biol. 2007, 312:61-76.
22. Kang S.A., Seol J.H., Kim J. The conserved WRPW motif of Hes6 mediates proteasomal degradation. Biochem Biophys Res Commun 2005, 332:33-36.
23. Assinder S.J., Stanton J.A., Prasad P.D. Transgelin: an actin-binding protein and tumor suppressor. Int. J. Biochem. Cell Biol. 2009, 41:482-486.
24. Shapland C., Hsuan J.J., Totty N.F., Lawson D. Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J. Cell Biol. 1993, 121:1065-1073.
25. Solway J., Seltzer J., Samaha F.F., Kim S., Alger L.E., Niu Q., Morrisey E.E., Ip H.S., Parmacek M.S. Structure and expression of a smooth muscle cell-specific gene, SM22 alpha. J. Biol. Chem. 1995, 270:13460-13469.
26. Han M., Dong L.H., Zheng B., Shi J.H., Wen J.K., Cheng Y. Smooth muscle 22 alpha maintains the differentiated phenotype of vascular smooth muscle cells by inducing filamentous actin bundling. Life Sci. 2009, 84:394-401.
27. Li L., Liu Z., Mercer B., Overbeek P., Olson E.N. Evidence for serum response factor-mediated regulatory networks governing SM22alpha transcription in smooth, skeletal, and cardiac muscle cells. Dev. Biol. 1997, 187:311-321.
28. Yu H., Konigshoff M., Jayachandran A., Handley D., Seeger W., Kaminski N., Eickelberg O. Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J. 2008, 22:1778-1789.
29. Koyano-Nakagawa N., Kim J., Anderson D., Kintner C. Hes6 acts in a positive feedback loop with the neurogenins to promote neuronal differentiation. Development 2000, 127:4203-4216.
30. Fior R., Henrique D. A novel hes5/hes6 circuitry of negative regulation controls Notch activity during neurogenesis. Dev. Biol. 2005, 281:318-333.
31. Vilas-Boas F., Henrique D. HES6-1 and HES6-2 function through different mechanisms during neuronal differentiation. PLoS ONE 2010, 5:e15459.
32. Murai K., Philpott A., Jones P.H. Hes6 is required for the neurogenic activity of neurogenin and NeuroD. PLoS ONE 2011, 6:e27880.
33. Bae S., Bessho Y., Hojo M., Kageyama R. The bHLH gene Hes6, an inhibitor of Hes1, promotes neuronal differentiation. Development 2000, 127:2933-2943.
34. Gratton M.O., Torban E., Jasmin S.B., Theriault F.M., German M.S., Stifani S. Hes6 promotes cortical neurogenesis and inhibits Hes1 transcription repression activity by multiple mechanisms. Mol. Cell Biol. 2003, 23:6922-6935.
35. Raimondi L., Ciarapica R., De Salvo M., Verginelli F., Gueguen M., Martini C., De Sio L., Cortese G., Locatelli M., Dang T.P., Carlesso N., Miele L., Stifani S., Limon I., Locatelli F., Rota R. Inhibition of Notch3 signaling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumor cell growth in vitro and in vivo. Cell Death Differ. 2011.
36. Roma J., Masia A., Reventos J., Sanchez de Toledo J., Gallego S. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin. Cancer Res. 2011, 17:505-513.
37. Sang L., Coller H.A., Roberts J.M. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 2008, 321:1095-1100.
38. Belyea B.C., Naini S., Bentley R.C., Linardic C.M. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Clin Cancer Res 2011, 17:7324-7336.
39. Meech R., Gomez M., Woolley C., Barro M., Hulin J.A., Walcott E.C., Delgado J., Makarenkova H.P. The homeobox transcription factor Barx2 regulates plasticity of young primary myofibers. PLoS ONE 2010, 5:e11612.
40. Meech R., Gonzalez K.N., Barro M., Gromova A., Zhuang L., Hulin J.A., Makarenkova H.P. Barx2 is expressed in satellite cells and is required for normal muscle growth and regeneration. Stem Cells 2012, 30:253-265.
41. Makarenkova H.P., Gonzalez K.N., Kiosses W.B., Meech R. Barx2 controls myoblast fusion and promotes MyoD-mediated activation of the smooth muscle alpha-actin gene. J. Biol. Chem. 2009, 284:14866-14874.
42. Meech R., Makarenkova H., Edelman D.B., Jones F.S. The homeodomain protein Barx2 promotes myogenic differentiation and is regulated by myogenic regulatory factors. J. Biol. Chem. 2003, 278:8269-8278.
43. Olson L.E., Zhang J., Taylor H., Rose D.W., Rosenfeld M.G. Barx2 functions through distinct corepressor classes to regulate hair follicle remodeling. Proc. Natl. Acad. Sci. USA 2005, 102:3708-3713.
44. Gramantieri L., Giovannini C., Lanzi A., Chieco P., Ravaioli M., Venturi A., Grazi G.L., Bolondi L. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int. 2007, 27:997-1007.
45. Dijkman R., van Doorn R., Szuhai K., Willemze R., Vermeer M.H., Tensen C.P. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007, 109:1720-1727.
46. Somasundaram K., Reddy S.P., Vinnakota K., Britto R., Subbarayan M., Nambiar S., Hebbar A., Samuel C., Shetty M., Sreepathi H.K., Santosh V., Hegde A.S., Hegde S., Kondaiah P., Rao M.R. Upregulation of ASCL1 and inhibition of notch signaling pathway characterize progressive astrocytoma. Oncogene 2005, 24:7073-7083.
47. Vias M., Massie C.E., East P., Scott H., Warren A., Zhou Z., Nikitin A.Y., Neal D.E., Mills I.G. Pro-neural transcription factors as cancer markers. BMC Med. Genomics 2008, 1:17.
48. Qi J., Nakayama K., Cardiff R.D., Borowsky A.D., Kaul K., Williams R., Krajewski S., Mercola D., Carpenter P.M., Bowtell D., Ronai Z.A. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 2010, 18:23-38.
49. Hartman J., Lam E.W., Gustafsson J.A., Strom A. Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation. Breast Cancer Res. 2009, 11:R79.
50. Haapa-Paananen S., Kiviluoto S., Waltari M., Puputti M., Mpindi J.P., Kohonen P., Tynninen O., Haapasalo H., Joensuu H., Perala M., Kallioniemi O. HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. Oncogene 2011.
51. Swearingen M.L., Sun D., Bourner M., Weinstein E.J. Detection of differentially expressed HES-6 gene in metastatic colon carcinoma by combination of suppression subtractive hybridization and cDNA library array. Cancer Lett. 2003, 198:229-239.